Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccin...( Findings Confirm Potency of...),Health

Findings Confirm Potency of Poly-ICR as Vaccine Adjuvant

SAN DIEGO, Oct. 8 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today presented positive data from preclinical studies using its proprietary Toll-like Receptor 3 agonist, Poly IC-Poly Arginine (Poly-ICR), at the World Vaccine Congress 2008 in Lyon, France. Study results demonstrated Poly-ICR to be a potent vaccine adjuvant targeting the Toll-like Receptor 3 (TLR3) pathway. Data showed that Poly-ICR, in combination with model antigens, elicits strong anti-target antibody and CD8 T-cell immune responses. These findings demonstrate the versatility of Poly-ICR, suggesting that the compound may possess broad potential for use in both therapeutic and prophylactic vaccines.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

Additional study findings presented today by Peter Emtage, Ph.D., Nventa's vice president of research and development, include:

-- Poly-ICR is stable and resistant to degradation by RNAses in

human serum;

-- Poly-ICR induces significant cytokine and chemokine production;

-- Poly-ICR matures dendritic cells, known as "the teachers of the

immune system".

In addition to incorporating Poly-ICR into future internal product candidates, Nventa is pursuing the development of Poly-ICR for topical application for the treatment of genital warts (GW) and actinic keratosis, a premalignant condition of the skin.

The company is also currently providing access to Poly-ICR to multiple leading vaccine developers in the U.S. and abroad, who are evaluating Poly-ICR for potential use into a wide range of vaccine products.

"These findings have confirmed the potency of Poly-ICR and highlighted the broad applicability of this compound for potential use in therapeutic and prophylactic vaccines," said
'/>"/>